Beta-1A - Latest Advances

Drug-induced osteoporosis/osteopenia: a pharmacovigilance analysis using the FDA Adverse Event Reporting System database.

Journal: Clinical and experimental rheumatology

Published: September 22, 2025

Evaluating Efficacy Outcomes in Pediatric Multiple Sclerosis Patients While Using Avonex or Plegridy via USNPMSC Registry.

Journal: Journal of child neurology

Published: September 16, 2025

Matching-adjusted indirect comparisons of diroximel fumarate, ocrelizumab and interferon beta-1a for relapsing multiple sclerosis.

Journal: Journal of comparative effectiveness research

Published: September 12, 2025

Beta Interferon 1a and Laquinimod Differentially Affect Coagulation-Related Gene Expression in Multiple Sclerosis Patients: Implications for Clinical Efficacy and Side Effects.

Journal: International journal of molecular sciences

Published: August 31, 2025

Combined intrathecal and intravenous exosome injection efficiency in a multiple sclerosis patient: a case report.

Journal: Cellular and molecular biology (Noisy-le-Grand, France)

Published: August 15, 2025

Selected aspects of epidemiology of multiple sclerosis in Poland: a multicenter pilot study.

Journal: Neurologia i neurochirurgia polska

Published: July 21, 2025

Bridging pharmacovigilance and genetic insight: investigating drugs and indications for breast cancer risk in women with autoimmune diseases.

Journal: Journal of translational medicine

Published: July 17, 2025

Outcomes of older patients with multiple sclerosis treated with interferon beta-1a or peginterferon beta-1a in MS PATHS.

Journal: Neurodegenerative disease management

Published: July 15, 2025

Therapeutic evaluation of immunomodulators and immunosuppressants in progressive multiple sclerosis: summary of a Cochrane systematic review.

Journal: Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology

Published: June 15, 2025

A multicentre, prospective, randomized, open-label pragmatic trial to compare the effectiveness and safety of interferon beta-1a and glatiramer-acetate in paediatric patients affected by Multiple Sclerosis.

Journal: Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology

Published: June 11, 2025

What Is the Evidence on Immunomodulators and Immunosuppressants for Progressive Multiple Sclerosis? - A Cochrane Review Summary with Commentary.

Journal: NeuroRehabilitation

Published: June 09, 2025

Expression profiling of Wnt/β-catenin, antimicrobial peptides, endoplasmic reticulum stress, and apoptosis signaling pathways and antioxidant/oxidant status in Oreochromis niloticus following Proteus mirabilis challenge: the palliative role of naringenin flavanone.

Journal: Fish & shellfish immunology

Published: May 28, 2025

Filters

Drug-induced osteoporosis/osteopenia: a pharmacovigilance analysis using the FDA Adverse Event Reporting System database.

Drug-induced osteoporosis/osteopenia: a pharmacovigilance analysis using the FDA Adverse Event Reporting System database.

Evaluating Efficacy Outcomes in Pediatric Multiple Sclerosis Patients While Using Avonex or Plegridy via USNPMSC Registry.

Evaluating Efficacy Outcomes in Pediatric Multiple Sclerosis Patients While Using Avonex or Plegridy via USNPMSC Registry.

Matching-adjusted indirect comparisons of diroximel fumarate, ocrelizumab and interferon beta-1a for relapsing multiple sclerosis.

Matching-adjusted indirect comparisons of diroximel fumarate, ocrelizumab and interferon beta-1a for relapsing multiple sclerosis.

Beta Interferon 1a and Laquinimod Differentially Affect Coagulation-Related Gene Expression in Multiple Sclerosis Patients: Implications for Clinical Efficacy and Side Effects.

Beta Interferon 1a and Laquinimod Differentially Affect Coagulation-Related Gene Expression in Multiple Sclerosis Patients: Implications for Clinical Efficacy and Side Effects.

Combined intrathecal and intravenous exosome injection efficiency in a multiple sclerosis patient: a case report.

Combined intrathecal and intravenous exosome injection efficiency in a multiple sclerosis patient: a case report.

Selected aspects of epidemiology of multiple sclerosis in Poland: a multicenter pilot study.

Selected aspects of epidemiology of multiple sclerosis in Poland: a multicenter pilot study.

Bridging pharmacovigilance and genetic insight: investigating drugs and indications for breast cancer risk in women with autoimmune diseases.

Bridging pharmacovigilance and genetic insight: investigating drugs and indications for breast cancer risk in women with autoimmune diseases.

Outcomes of older patients with multiple sclerosis treated with interferon beta-1a or peginterferon beta-1a in MS PATHS.

Outcomes of older patients with multiple sclerosis treated with interferon beta-1a or peginterferon beta-1a in MS PATHS.

Therapeutic evaluation of immunomodulators and immunosuppressants in progressive multiple sclerosis: summary of a Cochrane systematic review.

Therapeutic evaluation of immunomodulators and immunosuppressants in progressive multiple sclerosis: summary of a Cochrane systematic review.

A multicentre, prospective, randomized, open-label pragmatic trial to compare the effectiveness and safety of interferon beta-1a and glatiramer-acetate in paediatric patients affected by Multiple Sclerosis.

A multicentre, prospective, randomized, open-label pragmatic trial to compare the effectiveness and safety of interferon beta-1a and glatiramer-acetate in paediatric patients affected by Multiple Sclerosis.

What Is the Evidence on Immunomodulators and Immunosuppressants for Progressive Multiple Sclerosis? - A Cochrane Review Summary with Commentary.

What Is the Evidence on Immunomodulators and Immunosuppressants for Progressive Multiple Sclerosis? - A Cochrane Review Summary with Commentary.

Expression profiling of Wnt/β-catenin, antimicrobial peptides, endoplasmic reticulum stress, and apoptosis signaling pathways and antioxidant/oxidant status in Oreochromis niloticus following Proteus mirabilis challenge: the palliative role of naringenin flavanone.

Expression profiling of Wnt/β-catenin, antimicrobial peptides, endoplasmic reticulum stress, and apoptosis signaling pathways and antioxidant/oxidant status in Oreochromis niloticus following Proteus mirabilis challenge: the palliative role of naringenin flavanone.